AMICUS THERAPEUTICS INC Form S-8 July 02, 2014

As filed with the Securities and Exchange Commission on July 2, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

71-0869350

(State or other jurisdiction of

(I.R.S. Employer

incorporation or formation)

Identification Number)

1 Cedar Brook Drive, Cranbury, NJ

08512

(Address of Principal Executive Offices)

(Zip Code)

AMICUS THERAPEUTICS, INC. CASH

DEFERRAL PLAN

(Full title of the plan)

John F. Crowley

Chief Executive Officer

Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512

(Name and address of agent for service)

(609) 662-2000

(Telephone number, including area code, of agent for service)

Copy to:

Steven J. Abrams

Pepper Hamilton LLP

3000 Two Logan Square

Eighteenth and Arch Streets

Philadelphia, PA 19103

(215) 981-4000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o Accelerated filer x Non-accelerated filer o Smaller reporting company o

CALCULATION OF REGISTRATION FEE



(2) Estimated, pursuant to paragraph (h) of Rule 457 under the Securities Act of 1933, as amended (the Securities Act), solely for the purpose of calculating the registration fee.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Information required in Part I of Form S-8 to be contained in a prospectus meeting the requirements of Section 10(a) of the Securities Act is not required to be filed with the Securities and Exchange Commission (the Commission) and is omitted from this Registration Statement in accordance with the explanatory note to Part I of Form S-8 and Rule 428 under the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of documents by Reference.

The following documents, which have been filed by the Registrant with the Commission, are hereby incorporated by reference into this Registration Statement:

- (a) The Registrant s Annual Report on Form 10-K for the fiscal year ended December 31, 2013, filed with the Commission on March 3, 2014;
- (b) The Registrant s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014, filed with the Commission on May 5, 2014; and
- (c) The Registrant s Current Reports on Form 8-K filed with the Commission on January 8, 2014, January 13, 2014, March 3, 2014 (Film No. 14658206), March 4, 2014 (other than Item 7.01), April 10, 2014, April 25, 2014, April 29, 2014 (other than Item 7.01 and Exhibit 99.1), and June 16, 2014, and the Registrant s Amendments to Current Reports on Form 8-K filed with the Commission on February 4, 2014, February 12, 2014, and June 23, 2014.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents.

Item 4. Description of Securities.

The following description of the deferred compensation obligations of the Registrant under the Cash Deferral Plan is qualified by reference to the Cash Deferral Plan, which is included as an exhibit to this Registration Statement.

Under the Cash Deferral Plan, the Registrant will provide certain key employees, including the Company s named executive officers, and non-employee directors of the Registrant and its subsidiaries with the opportunity to defer the receipt of Compensation, as such term is defined in the Cash Deferral Plan.

Each eligible participant may elect to defer the receipt of base salary, bonus or director s fees in either a dollar amount or specified percentage. Such election shall become irrevocable for any Plan Year after December 31st; provided, however, that an initial election shall become irrevocable 30 days after a participant is first eligible to participate in the Cash Deferral Plan for that Plan Year. Participants in the Cash Deferral Plan may elect to re-defer receipt of any deferrals for an additional period of not less than five years if the election to defer receipt is made at least 12 months before the year in which the deferral would otherwise be distributed.

After a deferral election is made, the amount of Compensation the participant elects to defer shall be credited by the Registrant to the participant s account. The participant will have the opportunity to make hypothetical investments of the deferred amounts from among such investment options as the Compensation Committee may from time to time determine to offer, and all deemed income, earnings, and losses from such investments will be credited to the participant s account. A participant will be fully vested in all amounts in such account, including all deemed income, gains, and losses attributable thereto.

Payment of amounts in a participant s account shall be made to the participant (or in the event of the participant s death, to the beneficiary) pursuant to the participant s elected distribution date and may be made in lump sum or in installments; notwithstanding the foregoing, upon the first to occur of a separation from service, Disability (as such term is defined under the Cash Deferral Plan), death, or a Change in Control (as such term is defined under the Cash Deferral Plan), all remaining amounts in the participant s account, including any remaining installments, shall be paid as soon as practical following such event in lump sum.

All deferred amounts (including applicable earnings or losses) will for all purposes continue to be a part of the general funds

of the Registrant and the participant s account will at all times represent a general obligation of the Registrant. Each participant will be a general creditor of the Registrant with respect to the participant s account, and will not have a secured or preferred position with respect to such account. Nothing contained in the Cash Deferral Plan shall be deemed to create an escrow, trust, custodial account or fiduciary relationship of any kind or to eliminate any priority or preferred position of a participant in a bankruptcy matter with respect to claims for wages. Under the terms of the Cash Deferral Plan, the right of a participant in or to an account, benefit or payment under the Cash Deferral Plan shall not be subject in any manner to attachment or other legal process for the debts of such participant; and no such account, benefit or payment shall be subject to anticipation, alienation, sale, transfer, attachment, execution, garnishment, assignment or encumbrance.

anticipation, alienation, sale, transfer, attachment, execution, garnishment, assignment or encumbrance.
Item 5. Interests of Named Experts and Counsel.
Not applicable.
Item 6. Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify its officers and directors and certain other persons to the extent and under the circumstances set forth therein.
Article Seven of the Registrant s Restated Certificate of Incorporation (the <u>Certific</u> ate), and Article VII of the Registrant s Amended and Restated By-Laws (the <u>By-Laws</u>), provide that the Registrant will indemnify its directors, officers, employees and agents to the full extent permitted by Delaware General Corporation Law, including in circumstances in which indemnification is discretionary under such law. The indemnification provisions in the Certificate and By-Laws may be sufficiently broad to permit indemnification of said directors and officers for liabilities (including reimbursement for expenses incurred) arising under the Securities Act. The Registrant intends to maintain director and officer liability insurance, if available on reasonable terms, to insure said directors and officers against the costs of defense, settlement, or judgment under certain circumstances.
The Registrant has also entered into indemnification agreements with each of its current directors and certain of its officers (the <u>Indemnified Persons</u>). The indemnification agreements require, among other things, that the Registrant indemnify the Indemnified Person to the fullest extent permitted by law, and advance to such Indemnified Person all related expenses, subject to reimbursement if it is subsequently determined that indemnification is not permitted. In addition, the Registrant must, from time to time, make the good faith determination whether or not it is practicable for the Registrant to obtain and maintain insurance policies providing the Indemnified Persons with coverage for losses from wrongful acts, or to insure the Registrant s performance of its indemnification obligations under the indemnification agreements. The indemnification agreements are direct contractual obligations of the Registrant in favor of the Indemnified Person. Therefore, in the event that the By-Laws are subsequently changed to reduce the scope of indemnification, the Indemnified Persons will not be affected by such changes.
Item 7. Exemption from Registration Claimed.
Not applicable.

Item 8. Exhibits.

Exhibit Number	Description
4.1	Amicus Therapeutics, Inc. Cash Deferral Plan (incorporated by reference from the Company's current report on Form 8-K filed on July 2, 2014).
5.1	Opinion of Pepper Hamilton LLP*
23.1	Consent of Ernst & Young LLP*
23.2	Consent of Pepper Hamilton LLP (included in Exhibit 5.1 to this Registration Statement)*
24	Power of Attorney (included on the signature page of this Registration Statement)*

* Filed herewith

Item 9. Undertakings.
1. <u>Item 512(a) of Regulation S-K:</u>
The undersigned Registrant hereby undertakes:
(a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective Registration Statement; and,
(iii) to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.
<i>Provided, however</i> , that paragraphs (1)(a)(i) and (1)(a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
(b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
2. <u>Item 512(b) of Regulation S-K.</u>

The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933 each filing of the registrant s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act of 1934 (and, where applicable, each filing of an

8

employee benefit plan s annual report pursuant to Section 15(d) of the Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

3. Item 512(h) of Regulation S-K.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

4

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in Cranbury, New Jersey, on the 2nd day of July, 2014.

AMICUS THERAPEUTICS, INC.

By: /s/ John F. Crowley

Name: John F. Crowley

Title: President and Chief Executive Officer

POWER OF ATTORNEY

We, the undersigned officers and directors of Amicus Therapeutics, Inc., hereby severally constitute and appoint John F. Crowley and William D. Baird, III, and both or either one of them, our true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution in for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ John F. Crowley John F. Crowley	Chairman and Chief Executive Officer (Principal Executive Officer)	July 2, 2014
/s/ William D. Baird, III William D. Baird, III	Chief Financial Officer (Principal Financial Officer)	July 2, 2014
/s/ Daphne Quimi Daphne Quimi	Vice President, Finance and Controller (Principal Accounting Officer)	July 2, 2014
/s/ Sol J. Barer Ph.D. Sol J. Barer Ph.D.	Director	July 2, 2014
/s/ M. James Barrett Ph.D. M. James Barrett Ph.D.	Director	July 2, 2014
/s/ Robert Essner Robert Essner	Director	July 2, 2014

/s/ Donald J. Hayden , Jr. Donald J. Hayden , Jr.	Director	July 2, 2014
/s/ Ted W. Love, M.D. Ted W. Love, M.D.	Director	July 2, 2014
/s/ Margaret G. McGlynn, R.Ph. Margaret G. McGlynn, R.Ph.	Director	July 2, 2014
/s/ Michael G. Raab Michael G. Raab	Director	July 2, 2014
/s/ Glenn Sblendorio Glenn Sblendorio	Director	July 2, 2014
/s/ James N. Topper, M.D., Ph.D. James N. Topper, M.D., Ph.D.	Director	July 2, 2014

EXHIBIT INDEX

Exhibit Number	Description
4.1	Amicus Therapeutics, Inc. Cash Deferral Plan (incorporated by reference from the Company s current report on Form 8-K filed on July 2, 2014).
5.1	Opinion of Pepper Hamilton LLP*
23.1	Consent of Ernst & Young LLP*
23.2	Consent of Pepper Hamilton LLP (included in Exhibit 5.1 to this Registration Statement)*
24	Power of Attorney (included on the signature page of this Registration Statement)*
*	Filed berewith

6